Mauro E, Stefani PM, Gherlinzoni F. Adult Langerhans cell histiocytosis and immunomodulatory drugs: Review and analysis of thirty-four case reports. World J Hematol 2019; 8(1): 1-9 [DOI: 10.5315/wjh.v8.i1.1]
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Author contributions: Mauro E designed the paper, performed the research and wrote the manuscript; Stefani PM and Gherlinzoni F analyzed the data; all authors contributed to this manuscript.
Conflict-of-interest statement: Authors declare no conflicts of interest for this article.
Open-Access: This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Received: March 18, 2019 Peer-review started: March 19, 2019 First decision: September 17, 2019 Revised: October 26, 2019 Accepted: December 6, 2019 Article in press: December 6, 2019 Published online: December 20, 2019
Langerhans cell histiocytosis (LCH) is a rare neoplastic disease in dendritic cells. LCH is classified as either a single-system (SS) or multisystem (MS) disease. There is not a standard first-line treatment for LCH in adults. We analyzed the efficacy and safety of immunomodulatory drugs (IMiDs) by searching PubMed/MEDLINE for case reports previously published. The clinical response (nonactive disease or active disease that regressed) was 94% in SS and 53% in MS. IMiDs should only be considered for adults with cutaneous SS involvement; in MS, they should be used only for patients not eligible for more aggressive treatments.
Core tip: Langerhans cell histiocytosis (LCH) is a rare neoplastic disease derived from dendritic cells that is seen in children as well as in adults. There is not a standard first-line treatment in adults; no prospective trials have been undertaken on this population, and chemotherapy schedules are often reported from pediatric experiences with suboptimal efficacy and a higher toxicity in adults than in children. Immunomodulatory drugs (IMiDs), as less toxic therapeutic options, have been considered for treating LCH. We analyzed the efficacy and safety of IMiDs in adults with LCH from previously published research.
Citation: Mauro E, Stefani PM, Gherlinzoni F. Adult Langerhans cell histiocytosis and immunomodulatory drugs: Review and analysis of thirty-four case reports. World J Hematol 2019; 8(1): 1-9
Langerhans cell histiocytosis (LCH) is a rare neoplastic disease derived from dendritic cells that is seen in children as well as in adults. The LCH incidence is estimated to be 1-2 cases per million in adults[2,3]. The diagnosis of LCH is based on histologic and immunophenotypic evaluations of lesions: In particular, evidence of Langerhans cell infiltrates with a positivity for CD1a and/or CD207 (Langerin) as seen on an optical microscope or the presence of Birbeck granules as seen on an electronic microscope. Multiple organs may be involved in generating a broad spectrum of clinical manifestations[4,5], from a skin rash to an explosive disseminated disease. In particular, the disease may affect organs or organ systems, especially the bone, skin, pituitary gland, lymph nodes, liver, spleen, gut, central nervous system (CNS), bone marrow, and lungs, with focal or multifocal infiltrates[1,6], that results in different outcomes. The expert panel on behalf of the Euro-Histio-Net classified the disease as either single system LCH (SS-LCH) or multisystem LCH (MS-LCH) (two or more organs/system involved) with or without the involvement of high-risk organs such as bone marrow, spleen, liver or CNS. Recently, mutations in the BRAF gene have been reported in approximately 50% of cases, representing a breakthrough in understanding the pathogenesis of LCH[7-9]. In particular, BRAF mutations induce constitutive activation of downstream mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinases, offering new therapeutic targets for the MAPK pathway. Based on multifocal or focal LCH and on the involvement at special sites, the treatment changes. However, there is not a standard for first-line treatment for adults with LCH; no prospective trials have been undertaken on this population, and the therapy schedules are often reported from pediatric experiences[1,6,10]. Therefore, the treatment depends on the extent and severity of the disease at onset. In particular, the pediatric treatment schedule for vinblastine in combination with a prednisone has been used in adults but has a suboptimal efficacy and higher toxicity in adults than in children. Other therapeutic approaches for MS-LCH adults include monotherapy with cladribine, cytarabine, etoposide or polychemotherapy regimens[11-14]. According to the expert panel of Euro-Histio-Net, recommendations for first-line therapy are summarized in Table 1. Among the therapeutic options with activity against LCH, immunomodulatory drugs (IMiDs) have been taken into account. In LCH, a variety of cytokines, IL-1, IL-10, interferon gamma, granulocyte-macrophage colony stimulating factor and tumor necrosis factor alpha (TNF-α), are expressed at high levels and play key roles in the pathogenesis of disease. TNF-α is considered the major promoter for Langerhans cell proliferation and production from hematopoietic stem cells, and its expression is modulated by IMiDs. Here, we analyzed the efficacy and safety of IMiDs in LCH.
Radiotherapy (in case of neurological deficit, soft tissue involvement)
Multifocal SS-LCH without “organ risk”
SS-LCH (bone lesions)
Methotrexate 20 mg per week p.o/i.v.
Azathioprine 2 mg/kg/d p.o.
Thalidomide 100 mg/die p.o. (skin or soft tissue multifocal SS-LCH if symptomatic)
Symptomatic MS-LCH without “risk organs”
Cytarabine 100 mg/m2 d1-5 q4w i.v.
Etoposide 100 mg/m2 d1-5 q4w i.v.
Vinblastin/Prednisone (“pediatric like schedule”)
MS-LCH with “risk organs”
2-CDA 6 mg/m2 d1-5 q4w s.c./i.v.
Chemotherapy in case of progressive disease
In case of severe respiratory failure or major pulmonary failure consider lung transplantation
"Risk organs" contains hematopoietic system, spleen, liver, and central nervous system. LCH: Langerhans cell histiocytosis. SS-LCH: Single-system Langerhans cell histiocytosis; MS-LCH: Multisystem Langerhans cell histiocytosis; P-LCH: Pulmonary Langerhans cell histiocytosis; PUVA: Psolaren plus ultraviolet A.
To summarize the current experience of IMiDs as the treatment for LCH, we conducted a PubMed/MEDLINE search for case reports and case series from 1987 until 2018. The search items used were LCH, IMiDs, thalidomide, and lenalidomide; the limits set were case reports, human, and English, French and German languages. A total of 53 articles were found. Review articles, pediatric cases and in vitro analyses were excluded. A total of 29 articles about case reports or case series were found[10,17-44]. Six patients treated with thalidomide were included in the study for a toxicity and efficacy analysis. According to the Writing Group of the Histiocyte Society and recommendations from the Euro-Histio-Net, in all collected cases, the histopathological diagnosis was made with positivity of CD1a and/or Langherin (CD207) or the presence of Birbeck granules on electronic microscopy. All patients were treated with IMiDs. Moreover, evaluating every single case, we stratified the disease as SS-LCH or MS-LCH. Briefly: SS-LCH is defined as having one organ or system involved (in particular, bone with single or multiple lesions, skin, lymph node, hypothalamic-pituitary/CNS, lungs or other systems), and MS-LCH is defined as having two or more organs or systems involved. To assess the disease state after treatment, we applied the HS criteria to every case description. Briefly, if the authors reported that all signs and symptoms were resolved, we considered the described patients as having a nonactive disease (NAD); otherwise, the patients were classified as having active disease (AD). AD was further subdivided into regressive [active disease regressive (ADR); improvement in the symptoms or signs, with no new lesions], stable [Active disease stable (ADS); persistence of symptoms or signs, with no new lesions], or progressive disease (PD) (progression and/or appearance of new lesions).
A total of 34 patients (21 female and 13 male) were included in this study, including 17 SS-LCH and 17 MS-LCH patients. Detailed information of each patient is displayed in Table 2. The mean age at diagnosis was 45.3 years (range 20-73). The skin or mucocutaneous involvement was reported in 32 patients (94%), and these patients were considered as having only a single organ represented in the SS-LCH group. In addition, the following involved areas were reported: the genital/perineal zone in 22 patients, trunk in 10 patients, groins in 9 patients, axillary involvement in 7 patients, scalp in 5 patients, buccal/mucosal involvement in 5 patients, face in 4 patients, nails in 3 patients, neck in 2 patients, external auditory meatus in 1 patients, retroauricular zone 1 patients, and feet 1 patients. The other organs involved are reported in Table 3. Thalidomide was used in 32 patients, and lenalidomide was used in 2 patients. In 14 patients [7 SS-LCH (20.5%) and 7 MS-LCH (20.5%)], thalidomide was the first-line therapy, while in 20 patients (58.8%) IMiDs were the therapy that followed treatment with steroids, radiotherapy, surgery and chemotherapy. The details of treatment types are summarized in Table 4. The mean thalidomide dosage was 155 mg/d (range 50-500 mg), and the mean lenaldomide dosage was 25 mg/d in case study of Szturz et al and 10 mg/d in the case study by El-Safadi et al. The mean duration of therapy with IMiDs was 10.7 mo. Regarding adverse events, the authors reported fatigue/somnolence in 9 patients (22.5%), neuropathy in 6 patients (15%), constipation in 1 patient (2.5%), thrombosis in 1 patient(2.5%), skin rash in 1 patient(2.5%), and neutropenia in 1 patient (2.5%). Regarding the outcomes, considering NAD and ADR, the overall response rate was 73.5%; ADS was reported in 20.5% of patients, and PD was reported in 6% of patients. In the SS-LCH group, 16 patients (94%) achieved NAD/ADR and one patient (6%) achieved PD; in the MS-LCH group, 9 patients (53%) achieved NAD/ADR, 7 patients (41%) achieved a ADS and one patient had PD (Figure 1). After starting therapy, the follow-up was evaluable in 30 patients with any response (NAD/ADR/ADS/PD) at a mean of 11.6 mo (range 3-60). During follow-up, 7 patients (23.3%) (2 SS-LCH and 5 MS-LCH) were referred for other cytotoxic regimens because of relapse or suboptimal disease control.
PUVA: Psolaren plus ultraviolet A; IMiDs: Immunomodulatory drugs.
Because of the rarity of LCH, there are no standard therapies for adults, and no prospective trials have been undertaken on this setting population. According to the standard pediatric treatment, the vinblastine/prednisone treatment experience has been employed in adults; however, suboptimal efficacy and near universal toxicity have been reported. More recently, in a retrospective study, 35 adults (28 patients with MS-LCH) were treated with vinblastine and steroids as a first-line therapy, achieving an overall response rate of 71%. In this study, neutropenia was reported in 17% of patients, peripheral sensitive neuropathy (grade 2) in 26% of patients, and peripheral motor neuropathy (grade 2) in 3% of patients. As an alternative choice to vinblastine, other drugs, such as cladribine and cytosine arabinoside (ARA-c), have been considered in adults[1,11]. In particular, Saven et al conducted phase II trials with cladribine; in total, 13 patients were enrolled with an overall response rate of 75% with not only skin involvement but also soft tissues, lymph nodes, bones and pulmonary sites. The principal acute toxicity was hematologic with seven patients experiencing grade 3 or 4 neutropenia. On other hand, Cantu et al reported a retrospective study in which the poor response rate of ARA-c (21%) and the number of grade 3-4 toxic events (20%) were lowest of the three regimens shown in the study (vinblastine, cladribin and ARA-c) in patients with bone involvement. Retrospective analyses of the MACOP-B regimen (methorexate, doxorubicin, cyclosphamide, vincristine, prednisone, and bleomycin) have shown high efficacy in adults with LCH. However, this intensive treatment should be reserved for very severe cases. The BRAF-V600E mutation gene discovery paved the way for targeted therapies such as BRAF or MEK inhibitors in patients with LCH. In particular, vemurafenib is the first selective BRAF inhibitor approved by the United States Food and Drug Administration for malignant melanomas where BRAF mutations are expressed. However, in melanoma trials, vemurafenib was associated with considerable toxicity, including secondary squamous cell carcinoma, in over 30% of patients; moreover, the optimal dosage and duration of this treatment require further investigation. A variety of cytokines are expressed in LCH lesions. In particular, high levels of IL-1, IL-10 and TNF-α have been reported. IMiDs such as thalidomide and lenalidomide (an analogue of thalidomide) are cytokine modulators, especially for the inhibition of TNF-α; therefore, these drugs have been considered feasible candidates for the treatment of LCH. However, the evaluation of the efficacy and safety of IMiDs in LCH are limited mostly to case reports. To our knowledge, the study of McClain et al is the only phase II trial using thalidomide for LCH. In this study, the authors enrolled 16 patients: 12 pediatric patients (ages from birth to 3 years) and 4 adult patients (ages from 34 years to 46 years). Moreover, in 2004, Sander and coworkers reported a cutaneous LCH case successfully treated with thalidomide and reported ten cases published in the literature with similar clinical features. In 2013, European panel of experts established recommendations about the diagnosis and therapy. Grades of treatment recommendations were based on non-analytic studies (for example, case reports, case series, small retrospective studies, and expert opinions). After reviewing the literature[10,37], thalidomide was advised for LCH with mild symptoms in skin or soft tissue multifocal single system without risk organs involved. We performed a literature search for case reports on LCH treated with IMiDs and found 34 cases from 1987 to 2018. In our study, 94% of patients with SS-LCH achieved the best response (NAD/ADR) (Figure 1). In total, 50% of patients reported were MS-LCH (Table 3); in this analysis, the response rate for patients with NAD/ADR was 53%, and ADS was found in 41% of the patients. After somnolence, neuropathy is the most reported adverse event (16% of patients). In addition to the previously reported studies and recommendations from panel experts, we confirm in a larger setting of patients that IMiDs should be considered for treating adult patients with only mucocutaneous involvement; however, in the MS-LCH group, as expected, the IMiDs show a lower response rate. Therefore, other therapeutic approaches such as ARA-c, cladribin or vinblastine are recommended. In conclusion, IMiDs are a validated alternative to cytotoxic chemotherapeutic agents in most patients with SS-LCH; on other hand, considering the response rate in our study (53%) in patients with MS-LCH, IMiDs could be an evaluable choice for the treatment only in a limited number of patients based on age, compliance, performance status, expected toxicities, previous treatments, neuropathy or other comorbidities that make the patients not eligible for more aggressive treatments. Our study has several limitations. A publication bias toward more interesting and/or severe cases and successfully treated cases may lead to an over- or underestimation of the efficacy and safety of IMiDs in LCH. Prospective research for optimal treatment strategies for LCH should be warranted, albeit difficult to conduct for epidemiological reasons.
Different therapeutic strategies have been proposed for treatment of LCH in adults. The efficacy and safety of IMiDs have been reported in the treatment of multifocal SS-LCH (in particular skin or soft tissue if symptomatic). However, IMiDs could play a key role also in MS-LCH only in a limited setting of patients not eligible for more aggressive schedules.
Berres ML, Lim KP, Peters T, Price J, Takizawa H, Salmon H, Idoyaga J, Ruzo A, Lupo PJ, Hicks MJ, Shih A, Simko SJ, Abhyankar H, Chakraborty R, Leboeuf M, Beltrão M, Lira SA, Heym KM, Bigley V, Collin M, Manz MG, McClain K, Merad M, Allen CE. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.J Exp Med. 2014;211:669-683.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 224][Cited by in F6Publishing: 116][Article Influence: 32.0][Reference Citation Analysis (0)]
Diamond EL, Durham BH, Haroche J, Yao Z, Ma J, Parikh SA, Wang Z, Choi J, Kim E, Cohen-Aubart F, Lee SC, Gao Y, Micol JB, Campbell P, Walsh MP, Sylvester B, Dolgalev I, Aminova O, Heguy A, Zappile P, Nakitandwe J, Ganzel C, Dalton JD, Ellison DW, Estrada-Veras J, Lacouture M, Gahl WA, Stephens PJ, Miller VA, Ross JS, Ali SM, Briggs SR, Fasan O, Block J, Héritier S, Donadieu J, Solit DB, Hyman DM, Baselga J, Janku F, Taylor BS, Park CY, Amoura Z, Dogan A, Emile JF, Rosen N, Gruber TA, Abdel-Wahab O. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.Cancer Discov. 2016;6:154-165.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 220][Cited by in F6Publishing: 72][Article Influence: 36.7][Reference Citation Analysis (0)]
Egeler RM, Favara BE, van Meurs M, Laman JD, Claassen E. Differential In situ cytokine profiles of Langerhans-like cells and T cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment.Blood. 1999;94:4195-4201.
[PubMed] [DOI][Cited in This Article: ]
Bouyssou-Gauthier ML, Bedane C, Jaccard A, Dang PM, Labrousse F, Leboutet MJ, Bernard P, Bonnetblanc JM. [Multicentric histiocytosis with hematological involvement].Ann Dermatol Venereol. 1996;123:460-463.
[PubMed] [DOI][Cited in This Article: ]
Gnassia A, Gnassia R, Bovalent D, Puissant A, Goudal H. Histiocytosys X avec "granulome eosinophile vulvarâ: effect spectaculaire du thalidomide. Ann Dermatol Vénéréol.
[PubMed] [DOI][Cited in This Article: ]
Wollina U, Kaatz M, Krönert C, Schönlebe J, Schmalenberg H, Schreiber G, Köstler E, Haroske G. Cutaneous Langerhans cell histiocytosis with subsequent development of haematological malignancies. Report of two cases.Acta Dermatovenerol Alp Pannonica Adriat. 2006;15:79-84.
[PubMed] [DOI][Cited in This Article: ]
Haroche J, Cohen-Aubart F, Emile JF, Arnaud L, Maksud P, Charlotte F, Cluzel P, Drier A, Hervier B, Benameur N, Besnard S, Donadieu J, Amoura Z. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.Blood. 2013;121:1495-1500.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 344][Cited by in F6Publishing: 146][Article Influence: 38.2][Reference Citation Analysis (0)]